PepGen (NASDAQ:PEPG) Stock Price Target Raised at Wedbush

Key Points

• Wedbush raised its PepGen price target to $10 from $4 and maintained an “outperform” rating, implying about 117% upside from the stock’s current price.
• Analyst sentiment is broadly positive: PepGen has a “Moderate Buy” consensus rating and an average price target of $11.50, with five Buy, one Hold, and one Sell rating.
• PepGen shares rose 92.9% amid encouraging Phase 2 trial results, though its latest quarterly loss of $0.28 per share was slightly worse than analysts’ $0.27 estimate.

PepGen (NASDAQ:PEPG - Get Free Report) had its target price boosted by Wedbush from $4.00 to $10.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Wedbush's price target would indicate a potential upside of 116.92% from the company's current price.

Other research analysts also recently issued reports about the company. Wall Street Zen raised PepGen from a "sell" rating to a "hold" rating in a research note on Saturday. Bank of America raised PepGen from an "underperform" rating to a "neutral" rating and raised their price objective for the company from $2.50 to $6.00 in a research note on Tuesday. HC Wainwright restated a "buy" rating on shares of PepGen in a report on Wednesday, September 9th. Finally, Weiss Ratings raised PepGen from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, September 22nd. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, PepGen currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.50.

PepGen Trading Up 92.9%

NASDAQ:PEPG opened at $4.61 on Wednesday. The firm has a fifty day simple moving average of $2.69 and a two-hundred day simple moving average of $2.98. PepGen has a 12 month low of $1.31 and a 12 month high of $7.80. The stock has a market capitalization of $319.29 million, a price-to-earnings ratio of -3.52 and a beta of 2.02.

PepGen (NASDAQ:PEPG - Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.01). Equities analysts predict that PepGen will post -1.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PepGen

A number of hedge funds have recently bought and sold shares of PEPG. Brendel Financial Advisors LLC purchased a new position in PepGen during the third quarter worth about $306,000. Squarepoint Ops LLC increased its stake in PepGen by 260.9% in the 2nd quarter. Squarepoint Ops LLC now owns 529,083 shares of the company's stock valued at $952,000 after buying an additional 382,487 shares during the last quarter. Artia Global Partners LP bought a new position in shares of PepGen during the 2nd quarter worth approximately $370,000. AWM Investment Company Inc. bought a new position in shares of PepGen during the 2nd quarter worth approximately $1,080,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of PepGen during the 2nd quarter worth approximately $4,664,000. 58.01% of the stock is owned by hedge funds and other institutional investors.

More PepGen News

Here are the key news stories impacting PepGen this week:

• Positive Sentiment: PepGen said the 10 mg/kg dose in its Phase 2 FREEDOM2-DM1 trial showed the highest reported splicing correction and improvements across multiple functional measures—an encouraging signal for its DM1 drug and the main catalyst behind investor interest. Article: PepGen Announces Positive Phase 2 FREEDOM2-DM1 Results
• Positive Sentiment: Bank of America upgraded PEPG from “underperform” to “neutral” and raised its price target to $6 from $2.50, reflecting a more favorable view of the shares. Article: Bank of America Stock Recommendations
• Neutral Sentiment: PepGen reported $104.8 million in cash, providing funding for continued development, though the company remains loss-making. Article: PepGen Reports Phase 2 Results and Cash Position
• Negative Sentiment: The company proposed a $125 million public stock offering. The financing could strengthen its balance sheet, but issuing shares may dilute existing shareholders. Article: PepGen Launches $125M Public Stock Offering
• Negative Sentiment: PepGen reported a quarterly loss of $0.28 per share, slightly wider than the $0.27 loss analysts expected. Article: PepGen Reports Third Quarter 2026 Financial Results
• Negative Sentiment: Options trading included a sharp increase in put purchases, which may indicate heightened hedging or bearish positioning. Article: Traders Purchase Put Options on PepGen

PepGen Company Profile

PepGen Inc. is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company's technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing. PepGen's platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.